NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

You can’t legitimately compare an immature line with dozens of censors with a mature line with three censors.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145451/

For Case 2, our work tested the effects on power of adding the LTFU in the control arm when the treatment does (in reality) provide benefit.

Results for Case 2 show major impairment of power, thereupon entailing a sharp reduction in anticipated ability to detect the effectiveness of a treatment that (otherwise) really does yield an advantage.

There was a km calculator someone provided on ihub years ago, and if you added censors prior to the median, your survival improved.

Moreover, the argument of comparison is for not, where NWBO’s position is that there is crossover efficacy.